INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer

INmune Bio, Inc. announced today the US FDA has cleared the Investigational New Drug (IND) application for INKmune™, a novel natural killer cell immunotherapy, for a Phase I/II open-label clinical trial for the treatment of metastatic castration-resistant prostate cancer.